This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
‘Strongly Positioned To Move The Business Forward’: Race Oncology Appoints New CEO
Clincal stage biopharmaceutical company Race Oncology (ASX:RAC) says Tillett will work alongside executive director Dr Pete Smith, to advance the company’s strategic, clinical and commercialisation plans for its core asset reformulated bisantrene, RC220. Read more here.